{
    "eid": "2-s2.0-85120625176",
    "title": "The Use of SGLT2i and GLP-1 RA in patients with type 2 diabetes in thailand: Evidence review and recommendations",
    "cover-date": "2021-11-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Medicine (all)",
            "@code": "2700",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Cardiovascular diseases",
        "Chronic kidney disease",
        "Clinical outcomes",
        "GLP-1 RA",
        "SGLT2i",
        "Type 2 diabetes mellitus"
    ],
    "authors": [
        "Rungroj Krittayaphong",
        "Bancha Satirapoj",
        "Boonsong Ongphiphadhanakul",
        "Kriengsak Vareesangthip",
        "Sompongse Suwanwalaikorn",
        "Wacin Buddhari"
    ],
    "citedby-count": 0,
    "ref-count": 90,
    "ref-list": [
        "Global economic burden of diabetes in adults: projections from 2015 to 2030",
        "Diabetes in Thailand: status and policy",
        "The prevalence and management of diabetes in Thai adults: The international collaborative study of cardiovascular disease in Asia",
        "Prevalence of dyslipidemia associated with complications in diabetic patients: A nationwide study in Thailand",
        "Prevalence of diabetes and relationship with socioeconomic status in the thai population: National Health Examination Survey, 2004-2014",
        "Thailand diabetes registry (TDR) project: clinical status and long term vascular complications in diabetic patients",
        "Prevalence and associated factors of ischemic heart disease (IHD) among patients with diabetes mellitus: A nation-wide, cross-sectional survey",
        "Assessment and prevalences of diabetic complications in 722 Thai type 2 diabetes patients",
        "Risk factors for cardiovascular disease mortality among 86866 members of the Thai Cohort Study, 2005-2010",
        "Prevalence and clinical significance of diabetes in Asian versus white patients with heart failure",
        "Heart failure clinical trials in east and Southeast Asia: Understanding the importance and defining the next steps",
        "Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry",
        "Heart failure mortality compared between elderly and non-elderly Thai patients",
        "Diagnosis and management of type 2 diabetic kidney disease",
        "Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014",
        "Temporal trends in the prevalence of diabetic kidney disease in the United States",
        "Impaired glomerular filtration rate in type 2 diabetes mellitus subjects: A nationwide cross-sectional study in Thailand",
        "The association between renal function and neurological diseases in type 2 diabetes: A multicenter nationwide crosssectional study",
        "Associations of renal function with diabetic retinopathy and visual impairment in type 2 diabetes: A multicenter nationwide cross-sectional study",
        "Survival rates and mortality risk factors of Thai patients with type 2 diabetes mellitus",
        "Cardiovascular disease and risk management: standards of medical care in diabetes-2019",
        "Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a Diabetes Care Editors Expert Forum",
        "SGLT2 inhibitors and the diabetic kidney",
        "Dapagliflozin in patients with chronic kidney disease",
        "Canagliflozin and renal outcomes in type 2 diabetes and nephropathy",
        "A review of the efficacy and safety of sodium-glucose cotransporter 2 inhibitors: A focus on diabetic ketoacidosis",
        "Efficacy and safety of sodium-glucose co-Transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-Analysis",
        "No disparity of the efficacy and all-cause mortality between Asian and non-Asian type 2 diabetes patients with sodium-glucose cotransporter 2 inhibitors treatment: A meta-Analysis",
        "SGLT2 inhibitors in combination therapy: From mechanisms to clinical considerations in type 2 diabetes management",
        "Dapagliflozin and cardiovascular outcomes in type 2 diabetes",
        "Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)",
        "SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-Analysis of cardiovascular outcome trials",
        "Effectiveness of long-Term treatment with SGLT2 inhibitors: real-world evidence from a specialized diabetes center",
        "Dapagliflozin treatment for type 2 diabetes: A systematic review and meta-Analysis of randomized controlled trials",
        "Effectiveness and safety of sodium-glucose co-Transporter-2 inhibitors in Thai adults with type 2 diabetes mellitus: A real-world study",
        "Comparative safety of the sodium glucose co-Transporter 2 (SGLT2) inhibitors: A systematic review and meta-Analysis",
        "Cost utility of sodium-glucose cotransporter 2 inhibitors in the treatment of metformin monotherapy failed type 2 diabetes patients: A systematic review and metaanalysis",
        "Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction",
        "Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study",
        "SGLT-2 inhibitors for COVID-19-A miracle waiting to happen or just another beat around the bush?",
        "A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials",
        "Glucagonlike peptide-1 mimetics, optimal for Asian type 2 diabetes patients with and without overweight/obesity: meta-Analysis of randomized controlled trials",
        "Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: A systematic review and meta-Analysis",
        "Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: A systematic review and network meta-Analysis",
        "Pharmacologic management of type 2 diabetes mellitus: Available therapies",
        "Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-Analysis of economic evaluation studies",
        "Cost-benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in Thailand",
        "Combining glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors to target multiple organ defects in type 2 diabetes",
        "Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes",
        "Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease",
        "Empagliflozin and cardiovascular outcomes in asian patients with type 2 diabetes and established cardiovascular disease-results from EMPA-REG OUTCOME(\u00ae)",
        "Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study)",
        "Canagliflozin and cardiovascular and renal events in type 2 diabetes",
        "Cardiovascular outcomes with ertugliflozin in type 2 diabetes",
        "Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: A metaanalysis",
        "SGLT-2i and cardiovascular outcomes: A meta-Analysis of The Asian Cohort",
        "Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucoselowering drugs: The CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors)",
        "Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: The CVD-REAL 2 study",
        "Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study",
        "Liraglutide and cardiovascular outcomes in type 2 diabetes",
        "Semaglutide and cardiovascular outcomes in patients with type 2 diabetes",
        "Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes",
        "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebocontrolled trial",
        "Lixisenatide in patients with type 2 diabetes and acute coronary syndrome",
        "Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes",
        "Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebocontrolled trial",
        "Comparison of the effects of glucagon-like peptide receptor agonists and sodiumglucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus",
        "Asian subpopulations may exhibit greater cardiovascular benefit from long-Acting glucagonlike peptide 1 receptor agonists: A meta-Analysis of cardiovascular outcome trials",
        "Effect of dapagliflozin on clinical outcomes in patients with chronic kidney disease, with and without cardiovascular disease",
        "Empagliflozin and progression of kidney disease in type 2 diabetes",
        "Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME(\u00ae) trial",
        "Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function",
        "Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: An analysis from the DECLARE-TIMI 58 randomised trial",
        "SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-Analysis",
        "Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease",
        "Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): A multinational observational cohort study",
        "Liraglutide and renal outcomes in type 2 diabetes",
        "Dulaglutide and renal outcomes in type 2 diabetes: An exploratory analysis of the REWIND randomised, placebo-controlled trial",
        "Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: An exploratory analysis of the ELIXA randomised, placebo-controlled trial",
        "Renal outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)",
        "Sotagliflozin in patients with diabetes and chronic kidney disease",
        "Sotagliflozin in patients with diabetes and recent worsening heart failure",
        "Dapagliflozin in patients with heart failure and reduced ejection fraction",
        "Cardiovascular and renal outcomes with empagliflozin in heart failure",
        "2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/ American Heart Association Task Force on practice guidelines",
        "Prevalence and risk factors of chronic kidney disease in the Thai adult population: Thai SEEK study",
        "Metabolic syndrome and its relation to chronic kidney disease in a Southeast Asian population",
        "Effect of sodium-glucose cotransporter 2 inhibitor on proximal tubular function and injury in patients with type 2 diabetes: A randomized controlled trial"
    ],
    "affiliation": [
        {
            "affiliation-city": "Nakhon Pathom",
            "@id": "60012718",
            "affilname": "Mahidol University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60012718",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60006964",
            "affilname": "Phramongkutklao College of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006964",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "AstraZeneca"
    ]
}